Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0RVQLM
ADC Name
Belantamab-Compound (Ia)
Synonyms
Belantamab Compound (Ia)
   Click to Show/Hide
Organization
Orum Therapeutics, Inc.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Multiple myeloma [ICD11:2A83]
Investigative
Drug-to-Antibody Ratio
8
Structure
Antibody Name
Belantamab
  Antibody Info 
Antigen Name
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
  Antigen Info 
Payload Name
NeoDegrader P1
  Payload Info 
Therapeutic Target
Protein cereblon (CRBN)
  Target Info 
Linker Name
Belantamab-Compound (Ia) linker
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 7 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
87
pM
KMS-12-BM cells
Plasma cell myeloma
Half Maximal Inhibitory Concentration (IC50) 
0.12
nM
OPM-2 cells
Plasma cell myeloma
Half Maximal Inhibitory Concentration (IC50) 
0.2
nM
MOLP-2 cells
Plasma cell myeloma
Half Maximal Inhibitory Concentration (IC50) 
0.21
nM
MM1.S cells
Plasma cell myeloma
Half Maximal Inhibitory Concentration (IC50) 
3.17
nM
LP-1 cells
Plasma cell myeloma
Half Maximal Inhibitory Concentration (IC50) 
11.9
nM
NCI-H929 cells
Plasma cell myeloma
Half Maximal Inhibitory Concentration (IC50) 
68.4
nM
MM1.R cells
Plasma cell myeloma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 7 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 87.00 pM Positive BCMA expression (BCMA+++/++)
Method Description
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model Plasma cell myeloma KMS-12-BM cells CVCL_1334
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.12 nM Positive BCMA expression (BCMA+++/++)
Method Description
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model Plasma cell myeloma OPM-2 cells CVCL_1625
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.20 nM Positive BCMA expression (BCMA+++/++)
Method Description
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model Plasma cell myeloma MOLP-2 cells CVCL_2123
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.21 nM Positive BCMA expression (BCMA+++/++)
Method Description
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model Plasma cell myeloma MM1.S cells CVCL_8792
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 3.17 nM Positive BCMA expression (BCMA+++/++)
Method Description
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model Plasma cell myeloma LP-1 cells CVCL_0012
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 11.90 nM Positive BCMA expression (BCMA+++/++)
Method Description
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model Plasma cell myeloma NCI-H929 cells CVCL_1600
Experiment 7 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 68.40 nM Positive BCMA expression (BCMA+++/++)
Method Description
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model Plasma cell myeloma MM1.R cells CVCL_8794
References
Ref 1 Neodegrader conjugates; 2021-10-07.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.